Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTE4KHA)

• DTT Name: Amyloid beta A4 protein (APP) DTT Info
• Gene Name: APP

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aducanumab	DM51JW4	Alzheimer disease	8A20	Approved	[1]
Florbetapir F-18	DMJ8A3Z	Diagnostic imaging	N.A.	Approved	[2]
GV-971	DMTMA5W	Alzheimer disease	8A20	Approved in China	[3]
Lecanemab	DMW03YD	Alzheimer disease	8A20	Approved	[4]
Nirogacestat	DMUP5Z0	Desmoid tumour	2F7C	Approved	[5]

36 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALZT-OP1	DMG5BTD	Alzheimer disease	8A20	Phase 3	[6]
Bapineuzumab	DMHQ5GK	Alzheimer disease	8A20	Phase 3	[7]
Crenezumab	DM7QI29	Alzheimer disease	8A20	Phase 3	[8]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
Donanemab	DMPGLIO	Alzheimer disease	8A20	Phase 3	[10]
Gantenerumab	DMWX90U	Alzheimer disease	8A20	Phase 3	[11]
NI-101	DMJ2KIE	Alzheimer disease	8A20	Phase 3	[12]
Solanezumab	DM0HIU5	Alzheimer disease	8A20	Phase 3	[13]
Tramiprosate	DM7BSRH	Alzheimer disease	8A20	Phase 3	[14]
CAD-106	DM31VZT	Alzheimer disease	8A20	Phase 2/3	[15]
ABBV-916	DMGSCJC	Alzheimer disease	8A20	Phase 2	[16]
AD-35	DMVDQO6	Alzheimer disease	8A20	Phase 2	[17]
ALZ-801	DM7ZQAT	Alzheimer disease	8A20	Phase 2	[18]
AN-1792	DM3JNXS	Alzheimer disease	8A20	Phase 2	[19]
FRM-0962	DM9ORUW	Alzheimer disease	8A20	Phase 2	[20]
GSK933776A	DMX27Q1	Alzheimer disease	8A20	Phase 2	[21]
Myo-inositol	DMQKSGI	Alzheimer disease	8A20	Phase 2	[22]
NIC5-15	DMG7XOC	Alzheimer disease	8A20	Phase 2	[23]
Ponezumab	DMIAZ13	Alzheimer disease	8A20	Phase 2	[24]
T-817MA	DMD72F4	Alzheimer disease	8A20	Phase 2	[11]
Trontinemab	DMNCLHJ	Alzheimer disease	8A20	Phase 2	[25]
UB-311	DM4NXWE	Alzheimer disease	8A20	Phase 2	[26]
ACI-24	DM5YDSU	Alzheimer disease	8A20	Phase 1/2	[27]
EB-101	DMH2NKD	Dystrophic epidermolysis bullosa	EC32	Phase 1/2	[8]
11C-6-Me-BTA-1	DMICUPT	Alzheimer disease	8A20	Phase 1	[28]
11C-AZD-2184	DMYVDXW	Alzheimer disease	8A20	Phase 1	[29]
AAB-003/PF-05236812	DM92RQT	Alzheimer disease	8A20	Phase 1	[8]
ACU193	DM5BISI	Alzheimer disease	8A20	Phase 1	[30]
Affitope AD-01	DM0I8RZ	Alzheimer disease	8A20	Phase 1	[31]
Anti-N3pG-Abeta antibody	DMRWI7E	Alzheimer disease	8A20	Phase 1	[32]
ANVS301	DMHT1AS	Alzheimer disease	8A20	Phase 1	[33]
BEY2153	DMCB2Z0	Alzheimer disease	8A20	Phase 1	[34]
DWP-09031	DM4XZY9	Alzheimer disease	8A20	Phase 1	[8]
LY3372993	DMACGI7	Alzheimer disease	8A20	Phase 1	[35]
SAR228810	DMTFAGU	Alzheimer disease	8A20	Phase 1	[36]
Systebryl	DMD23AX	Amyloidosis	5D00	Phase 1	[8]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Affitope AD-02	DMSF5VK	Alzheimer disease	8A20	Discontinued in Phase 2	[37]
RN6G	DM5P1KQ	Age-related macular degeneration	9B75.0	Discontinued in Phase 2	[38]
PF-05236812	DM68PYA	Alzheimer disease	8A20	Discontinued in Phase 1	[1]

3 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AAB-002	DMC7EQT	Alzheimer disease	8A20	Phase 0	[8]
NN-818	DMLNYGX	Brain injury	NA07.Z	Preclinical	[8]
Pepticlere	DMA5T3J	Alzheimer disease	8A20	Preclinical	[39]

66 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene	DM70ODN	Discovery agent	N.A.	Investigative	[40]
1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene	DMBCU6W	Discovery agent	N.A.	Investigative	[40]
1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene	DMEU3MN	Discovery agent	N.A.	Investigative	[40]
1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene	DM0D6JN	Discovery agent	N.A.	Investigative	[40]
1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene	DMQY75B	Discovery agent	N.A.	Investigative	[40]
11A1	DMFVP6K	Alzheimer disease	8A20	Investigative	[8]
123I-DRM-106	DMW172Q	Alzheimer disease	8A20	Investigative	[8]
18F-AV-45 dimer	DMAPI2G	Cerebral amyloid angiopathy	5D00.0	Investigative	[8]
2,5-bis(2-methoxyphenyl)thiophene	DMU5GKN	Discovery agent	N.A.	Investigative	[41]
2,5-bis(4-Hydroxyphenyl)thiophene	DMNQIGZ	Discovery agent	N.A.	Investigative	[41]
2,5-bis(4-methoxyphenyl)thiophene	DM30RNY	Discovery agent	N.A.	Investigative	[41]
2,5-bis(4-nitrophenyl)thiophene	DM3USOR	Discovery agent	N.A.	Investigative	[41]
2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol	DMFNQZS	Discovery agent	N.A.	Investigative	[40]
2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene	DMX8U32	Discovery agent	N.A.	Investigative	[41]
4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol	DMGHVW7	Discovery agent	N.A.	Investigative	[41]
4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine	DMOGMJ9	Discovery agent	N.A.	Investigative	[41]
4-(5-(4-aminophenyl)thiophen-2-yl)phenol	DM1UX89	Discovery agent	N.A.	Investigative	[41]
4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine	DMO9YH0	Discovery agent	N.A.	Investigative	[41]
4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol	DMCNLBZ	Discovery agent	N.A.	Investigative	[41]
5-hydroxy-2-(4-aminophenyl)benzofuran	DM8KON3	Discovery agent	N.A.	Investigative	[42]
5-hydroxy-2-(4-dimethylaminophenyl)benzofuran	DMYL0ZF	Discovery agent	N.A.	Investigative	[42]
5-hydroxy-2-(4-methylaminophenyl)benzofuran	DM4QC0R	Discovery agent	N.A.	Investigative	[42]
5-methoxy-2-(4-aminophenyl)benzofuran	DMW7IXL	Discovery agent	N.A.	Investigative	[42]
5-methoxy-2-(4-dimethylaminophenyl)benzofuran	DM3NUMG	Discovery agent	N.A.	Investigative	[42]
5-methoxy-2-(4-methylaminophenyl)benzofuran	DM5N1JX	Discovery agent	N.A.	Investigative	[42]
6-iodo-4'-dimethyaminoflavone	DMAL1UH	Discovery agent	N.A.	Investigative	[43]
6-iodo-4'-hydroxyflavone	DM5FZBI	Discovery agent	N.A.	Investigative	[43]
6-iodo-4'-methoxyflavone	DM6U9CY	Discovery agent	N.A.	Investigative	[43]
6-iodo-4'-methylaminoflavone	DM9GJAY	Discovery agent	N.A.	Investigative	[43]
A-887755	DM8IWUE	Alzheimer disease	8A20	Investigative	[8]
Abloid	DMKN10X	Alzheimer disease	8A20	Investigative	[8]
ACI-636	DMPLNTM	Alzheimer disease	8A20	Investigative	[8]
ACU-0101979	DM7ZWRN	Alzheimer disease	8A20	Investigative	[8]
AD-0802	DM23QND	Alzheimer disease	8A20	Investigative	[8]
ANA-5	DM3DPSO	Alzheimer disease	8A20	Investigative	[8]
Anticalin	DMQJ3ZL	Alzheimer disease	8A20	Investigative	[8]
ARC-069	DMSM1PV	Alzheimer disease	8A20	Investigative	[8]
ARN-2966	DMBE0H8	Alzheimer disease	8A20	Investigative	[8]
AS-602704	DMANU3W	Discovery agent	N.A.	Investigative	[44]
AZ4800	DMATC5P	Discovery agent	N.A.	Investigative	[45]
BAN-2203	DMX6KTO	Alzheimer disease	8A20	Investigative	[8]
CD45RB	DMFQVLW	Glioma	2A00.0	Investigative	[8]
Chrysamine -G	DMLEXN0	Discovery agent	N.A.	Investigative	[9]
CT-003230	DM3W6PQ	Cognitive impairment	6D71	Investigative	[8]
DBT-1339	DM09YI7	Alzheimer disease	8A20	Investigative	[8]
DEHYDROZINGERONE	DM9TWR7	Discovery agent	N.A.	Investigative	[9]
EDN-OL1	DMHCGIS	Alzheimer disease	8A20	Investigative	[8]
ELND-007	DM5G1SF	Alzheimer disease	8A20	Investigative	[46]
Gamma-secretase modulators	DMG7UPR	Alzheimer disease	8A20	Investigative	[8]
Gelsolin	DML0OUY	Discovery agent	N.A.	Investigative	[47]
IN-N01	DMI5N23	Brain injury	NA07.Z	Investigative	[8]
KMS-88009	DM2K81B	Alzheimer disease	8A20	Investigative	[8]
KNX-Monoclonal204	DMNWXCA	Alzheimer disease	8A20	Investigative	[8]
Methionine Sulfoxide	DMKE18W	Discovery agent	N.A.	Investigative	[48]
Mimovax	DM7DT20	Alzheimer disease	8A20	Investigative	[8]
PA-1637	DMUH203	Neurological disorder	6B60	Investigative	[8]
RECALL-VAX	DM1XFE9	Alzheimer disease	8A20	Investigative	[8]
SB-13	DM9O0AR	Discovery agent	N.A.	Investigative	[40]
SEM-606	DMDIZUT	Neurological disorder	6B60	Investigative	[8]
SEN-1500	DMKB2IJ	Alzheimer disease	8A20	Investigative	[8]
SP-08	DM2TRIZ	Alzheimer disease	8A20	Investigative	[8]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[49]
TKP-1001	DMDBUXR	Alzheimer disease	8A20	Investigative	[8]
Turmeric extracts	DM3QE8P	Alzheimer disease	8A20	Investigative	[8]
VK-11	DM7FQD0	Alzheimer disease	8A20	Investigative	[8]
VK-12	DMRQBEW	Solid tumour/cancer	2A00-2F9Z	Investigative	[8]

References

• [1] Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.
• [4] The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
• [9] Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
• [10] Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479.
• [13] Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
• [14] Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
• [15] The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31.
• [16] Clinical pipeline report, company report or official report of AbbVie
• [17] Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-alpha and IL-1beta in an Abeta25-35-induced Rat Model of Alzheimer's Disease. J Alzheimers Dis. 2017;56(4):1403-1417.
• [18] Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012.
• [19] Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006 Sep;169(3):1048-63.
• [20] Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014
• [21] Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569.
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014 Nov;10(11):911-20.
• [24] Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36.
• [25] Clinical pipeline report, company report or official report of Roche
• [26] Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7.
• [27] Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8: 36.
• [28] Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques. Nuklearmedizin. 2007;46(6):271-80.
• [29] Low background and high contrast PET imaging of amyloid-beta with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013 April; 40(4): 580-593.
• [30] ACU193, a Monoclonal Antibody that Selectively Binds Soluble A? Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan. J Prev Alzheimers Dis. 2023;10(1):19-24.
• [31] Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review. Int J Alzheimers Dis. 2012; 2012: 369808.
• [32] LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co.
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [34] Clinical pipeline report, company report or official report of BeyondBio
• [35] ClinicalTrials.gov (NCT04451408) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants. U.S.National Institutes of Health.
• [36] SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA). Alzheimer's & Dementia Volume 9, Issue 4, Supplement, July 2013, Pages P808-P809.
• [37] Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014 Mar;10(3):405-19.
• [38] Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29.
• [39] Preclinical trail of Pepticlere (DP-74) for treating Alzheimer's disease. ProteoTech Inc.
• [40] Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
• [41] Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
• [42] Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30.
• [43] Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60.
• [44] Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa. Drug Dev Ind Pharm. 2007 Jan;33(1):71-7.
• [45] First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J Biol Chem. 2012 Apr 6;287(15):11810-9.
• [46] Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease Volume 82, October 2015, Pages 385-396.
• [47] Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003 Jan 1;23(1):29-33.
• [48] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [49] Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.